相似文献
1
Coronavirus replication and pathogenesis: Implications for the recent outbreak of severe acute respiratory syndrome (SARS), and the challenge for vaccine development.
J Neurovirol. 2004 Apr;10(2):75-85. doi: 10.1080/13550280490280292.
2
[SARS, possible zoonosis in the area of conflict of pathogenic coronaviruses of animals].
Schweiz Arch Tierheilkd. 2003 Jul;145(7):316-22. doi: 10.1024/0036-7281.145.7.316.
3
Severe acute respiratory syndrome coronavirus pathogenesis, disease and vaccines: an update.
Pediatr Infect Dis J. 2004 Nov;23(11 Suppl):S207-14. doi: 10.1097/01.inf.0000144666.95284.05.
4
Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus.
Microbiol Mol Biol Rev. 2005 Dec;69(4):635-64. doi: 10.1128/MMBR.69.4.635-664.2005.
5
Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus.
J Virol. 2011 Jan;85(1):217-30. doi: 10.1128/JVI.01805-10. Epub 2010 Oct 27.
6
Treatment and vaccines for severe acute respiratory syndrome.
Lancet Infect Dis. 2005 Mar;5(3):147-55. doi: 10.1016/S1473-3099(05)01307-1.
7
Development of a SARS vaccine: an industrial perspective on the global race against a global disease.
Expert Rev Vaccines. 2003 Aug;2(4):465-7. doi: 10.1586/14760584.2.4.465.
8
Update on SARS research and other possibly zoonotic coronaviruses.
Int J Antimicrob Agents. 2010 Nov;36 Suppl 1:S21-5. doi: 10.1016/j.ijantimicag.2010.06.016. Epub 2010 Aug 30.
9
[Diagnosis, treatment, control and prevention of SARS-CoV-2 and coronavirus disease 2019: back to the future].
Sheng Wu Gong Cheng Xue Bao. 2020 Apr 25;36(4):571-592. doi: 10.13345/j.cjb.200115.
10
[SARS vaccines].
Nihon Rinsho. 2008 Oct;66(10):1971-6.
引用本文的文献
1
Pulmonary Function Test: A Mainstay for Evaluating Respiratory Health in Patients Recovered from COVID-19 Infection.
J Pharm Bioallied Sci. 2024 Dec;16(Suppl 4):S3318-S3321. doi: 10.4103/jpbs.jpbs_780_24. Epub 2024 Sep 20.
2
Incidence of Thrombosis in COVID-19 Patients Compared to Non-COVID-19 Sepsis Patients in the Intensive Care Unit.
J Clin Med. 2024 May 18;13(10):2974. doi: 10.3390/jcm13102974.
3
SARS-CoV-2 prevalence in domestic and wildlife animals: A genomic and docking based structural comprehensive review.
Heliyon. 2023 Aug 21;9(9):e19345. doi: 10.1016/j.heliyon.2023.e19345. eCollection 2023 Sep.
4
Coronavirus disease 2019 (COVID-19) update: From metabolic reprogramming to immunometabolism.
J Med Virol. 2022 Oct;94(10):4611-4627. doi: 10.1002/jmv.27929. Epub 2022 Jun 20.
5
Emergence of SARS-CoV-2 New Variants and Their Clinical Significance.
Can J Infect Dis Med Microbiol. 2022 May 28;2022:7336309. doi: 10.1155/2022/7336309. eCollection 2022.
6
Overview of the pathogenesis of COVID-19 (Review).
Exp Ther Med. 2021 Sep;22(3):1011. doi: 10.3892/etm.2021.10444. Epub 2021 Jul 15.
7
The Current Status and Challenges in the Development of Vaccines and Drugs against Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2).
Biomed Res Int. 2021 Jun 1;2021:8160860. doi: 10.1155/2021/8160860. eCollection 2021.
8
Molecular scaffolds from mother nature as possible lead compounds in drug design and discovery against coronaviruses: A landscape analysis of published literature and molecular docking studies.
Microb Pathog. 2021 Aug;157:104933. doi: 10.1016/j.micpath.2021.104933. Epub 2021 May 11.
9
The Inclusive Review on SARS-CoV-2 Biology, Epidemiology, Diagnosis, and Potential Management Options.
Curr Microbiol. 2021 Apr;78(4):1099-1114. doi: 10.1007/s00284-021-02396-x. Epub 2021 Feb 27.
10
Coronavirus helicases: attractive and unique targets of antiviral drug-development and therapeutic patents.
Expert Opin Ther Pat. 2021 Apr;31(4):339-350. doi: 10.1080/13543776.2021.1884224. Epub 2021 Apr 21.
本文引用的文献
1
Recombination and Coronavirus Defective Interfering RNAs.
Semin Virol. 1997;8(2):101-111. doi: 10.1006/smvy.1997.0109. Epub 2002 May 25.
2
SARS: lessons learned from other coronaviruses.
Viral Immunol. 2003;16(4):461-74. doi: 10.1089/088282403771926292.
3
Effects of an epitope-specific CD8+ T-cell response on murine coronavirus central nervous system disease: protection from virus replication and antigen spread and selection of epitope escape mutants.
J Virol. 2004 Feb;78(3):1150-9. doi: 10.1128/jvi.78.3.1150-1159.2004.
4
Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug design.
Nucleic Acids Res. 2003 Dec 15;31(24):7117-30. doi: 10.1093/nar/gkg916.
5
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus.
Nature. 2003 Nov 27;426(6965):450-4. doi: 10.1038/nature02145.
6
Detection of SARS coronavirus RNA in the cerebrospinal fluid of a patient with severe acute respiratory syndrome.
Clin Chem. 2003 Dec;49(12):2108-9. doi: 10.1373/clinchem.2003.025437.
7
Common RNA replication signals exist among group 2 coronaviruses: evidence for in vivo recombination between animal and human coronavirus molecules.
Virology. 2003 Oct 10;315(1):174-83. doi: 10.1016/s0042-6822(03)00511-7.
8
Virology: SARS virus infection of cats and ferrets.
Nature. 2003 Oct 30;425(6961):915. doi: 10.1038/425915a.
9
Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003.
Lancet. 2003 Oct 25;362(9393):1353-8. doi: 10.1016/s0140-6736(03)14630-2.
10
Antiviral Therapy for Hepatitis C.
Curr Treat Options Gastroenterol. 2003 Dec;6(6):445-453. doi: 10.1007/s11938-003-0046-1.
Zotero 插件